ClinicalTrials.gg
RecruitingNCT06812598Updated Jan 21, 2026

Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

An interventional study of Letermovir (0-24w) and Letermovir (0-14w) in Cytomegalovirus Infections and CMV, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by The First Affiliated Hospital of Soochow University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.

Planned enrollment
Largest of 17
330 · median 80
Started
2024
with 4 others
No phase
2 of 17
1 open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
The First Affiliated Hospital of Soochow University

Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one has the largest planned enrollment, is one of 5 that started in 2024, is one of 2 with no phase, and was the 16th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About letermovir

letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letermovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

After allogeneic hematopoietic stem cell transplantation (allo-HSCT), recipients are immunocompromised and at increased risk of complications, including cytomegalovirus (CMV) infection. International clinical guidelines for the management of CMV infection post-allo-HSCT recommend three main strategies: minimizing infection risk, prevention, and preemptive therapy. However, traditional antiviral agents have not been approved for CMV prophylaxis in allo-HSCT recipients and are associated with significant adverse effects and the development of resistance, leaving the CMV prevention needs of this patient population unmet. Recent studies have demonstrated that letermovir prevents potent and highly specific antiviral activity against CMV, and it has been approved for CMV prophylaxis within the first 100 days post-allo-HSCT. Furthermore, evidence suggests that extending letermovir administration up to 28 weeks further reduces the risk of CMV infection in the later post-transplant period without increasing drug-related mortality. In China, the post-allo-HSCT CMV prevention strategy faces challenges such as limited treatment options, unclear guideline recommendations, non-standardized drug usage in certain medical institutions, and insufficient monitoring. This study aims to provide robust, evidence-based support for the use of letermovir in high-risk CMV reactivation among adult allo-HSCT recipients, thereby broadening clinical treatment choices.

Read the detailed description

CMV late-onset infections following the discontinuation of letermovir have been reported in numerous clinical studies. During this period, transplant recipients remain in the critical phase of immune reconstitution, and further reducing the occurrence of CMV late-onset infections is crucial for improving transplant outcomes. International data have shown that extending the duration of letermovir prophylaxis can further reduce the risk of CMV infection.

In high-risk populations for CMV reactivation and recurrence, the risk of CMV viremia remains elevated even beyond 100 days post-transplant, with incidence rates ranging from 36% to 54%. Consequently, clinical guidelines recommend extending prophylaxis duration, monitoring periods, and shortening the intervals between tests for these high-risk groups. The Chinese Expert Consensus on the Management of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation (2022 Edition) suggests that for high-risk populations, particularly those with acute or chronic GVHD, consideration should be given to extending the treatment course or reinitiating CMV reactivation prevention until immunosuppressive therapy is reduced.

Currently, in China, there are no prospective clinical studies or high-level evidence regarding the extension of prophylactic therapy to reduce CMV late-onset infections in adult allo-HSCT recipients at high risk for CMV reactivation. This study aims to investigate the efficacy and safety of extending letermovir prophylaxis from week 14 to week 24 post-HSCT in patients at high risk of CMV reactivation, thereby offering additional therapeutic options for these patients.

03

Conditions studied

  • Cytomegalovirus Infections
  • CMV

Keywords

  • Letermovir
  • Allogeneic Hematopoietic Stem Cell Transplantation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patients have decided to undergo an initial hematopoietic stem cell transplantation (allo-HSCT).
  2. The patients are ≥18 years old.
  3. The patients are CMV seropositive prior to transplantation.
  4. The patients have at least one high-risk factor for CMV reactivation, including:

(1) Haploidentical transplantation, HLA-mismatched transplantation, or unrelated donor transplantation.

(2) The primary source of stem cells is cord blood. (3) A conditioning regimen including total body irradiation (TBI). (4) A prophylaxis regimen containing alemtuzumab or high-dose anti-thymocyte globulin (ATG).

5. The patients are able to comply with the study visit schedule, understand and agree to adhere to all protocol requirements, and have voluntarily signed the form to participate in the study.

6. The patients have no plans for reproduction from the date of consent until 90 days after the last dose of the study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received hematopoietic stem cell transplantation (allo-HSCT).
  2. Patients with evidence of CMV viremia at any time prior to enrollment.
  3. Patients with a history of CMV end-organ disease within 6 months prior to enrollment.
  4. Patients with suspected or known allergy to letermovir or any active or inactive components of similar drugs.
  5. Patients with severe hepatic impairment (defined as Class C).
  6. Patients with end-stage renal disease with a \< 10 mL/min.
  7. Patients requiring mechanical ventilation or experiencing hemodynamic instability at the time of enrollment.
  8. Patients who received any drug therapy within 28 days prior to enrollment.
  9. Patients who received or plan to receive any of the following treatments within 28 days prior to enrollment or during the study: cidofovir, CMV immune globulin, or any experimental CMV antiviral drugs/biological therapies.
  10. Patients who previously participated or are currently participating in any study involving a CMV vaccine or other CMV investigational drugs, or who plan to participate in such studies during this trial.
  11. Patients who are pregnant or breastfeeding at the time of enrollment or planning to become pregnant within 90 days after the last dose of study medication.
  12. Patients who test positive for antibodies (HIV-Ab) at any time prior to randomization, or who test positive for virus antibodies (HCV-Ab) with detectable HCV RNA, or for surface antigen (HBsAg) within 90 days prior to randomization. Laboratory testing for HIV, HBV, or HCV is allowed using locally acceptable methods.
  13. Patients with active solid , except for localized basal cell or squamous cell carcinoma of the skin or a condition currently under treatment (e.g., lymphoma).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    The patient will begin receiving prophylactic treatment with letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg orally once daily. If administered in combination with cyclosporine, the letermovir dose should be reduced to 240 mg orally once daily. Treatment will continue until 24 weeks post-transplant (approximately 170 days). During hospitalization, the study nurse will distribute the medication to the patient according to the treatment protocol and provide guidance on proper administration. The nurse will ensure the patient adheres to the prescribed dosing schedule and will document both the medication distribution and adherence.

    Drug: Letermovir (0-24w)

  • Other
    Control Group

    The patient will begin prophylactic treatment with letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg orally once daily. If used in combination with cyclosporine, the letermovir dose should be reduced to 240 mg orally once daily. The treatment will continue for up to 14 weeks post-transplant (approximately 100 days). In addition, the usage of the medication will be carefully monitored and documented.

    Drug: Letermovir (0-14w)

Interventions

  • DrugLetermovirStudies of LetermovirLetermovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will begin receiving prophylactic treatment with domestically produced letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg, administered orally once daily. If used in combination with cyclosporine, the dose should be reduced to 240 mg once daily. The treatment will continue until 24 weeks post-transplant (approximately 170 days).

  • DrugLetermovirStudies of LetermovirLetermovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will begin receiving prophylactic treatment with domestically produced letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg, administered orally once daily. If used in combination with cyclosporine, the dose should be reduced to 240 mg once daily. The treatment will continue until 14 weeks post-transplant (approximately 100 days).

06

What researchers measure

Primary outcomes

  1. The incidence of clinically significant CMV infection (csCMVi) within 24 weeks post-transplant

    csCMVi: the occurrence of CMV disease or CMV viremia requiring preemptive therapy

    Time frame: within 24 weeks following HSCT

Secondary outcomes

  1. Incidence of resistant or refractory CMV infection within 24 weeks post-transplant

    Refractory CMV viremia: CMV viral load remains unchanged or increases after 2 weeks of appropriate anti-CMV treatment. Refractory CMV disease: Symptoms or signs of CMV disease show no improvement or continue to progress after 2 weeks of appropriate anti-CMV treatment.

    Time frame: within 24 weeks following HSCT

  2. Time to initiation of preemptive therapy and duration of treatment for CMV infection within 24 weeks post-transplant

    Preemptive Therapy for CMV: A treatment strategy where antiviral medications are administered early, based on the detection of CMV reactivation (e.g., through viral load monitoring) before symptoms or disease develop, to prevent the progression to CMV disease.

    Time frame: within 24 weeks following HSCT

  3. Incidence and severity of acute graft-versus-host disease (GVHD) within 100 days post-transplant

    Acute GVHD: A complication that occurs shortly after allogeneic stem cell transplantation, where the donor's immune cells attack the recipient's tissues, typically affecting the skin, liver, and gastrointestinal tract. It usually develops within the first 100 days post-transplant and can range from mild to severe.

    Time frame: within 100 days following HSCT

  4. Incidence and severity of chronic GVHD within 24 weeks post-transplant

    Chronic GVHD: A long-term complication following allogeneic stem cell transplantation, where the donor's immune cells attack the recipient's healthy tissues, affecting organs such as the skin, liver, lungs, and eyes. It can range from mild to severe and may require prolonged immunosuppressive therapy.

    Time frame: within 24 weeks following HSCT

  5. Incidence and severity of all adverse events (AEs) within 24 weeks post-transplant

    Adverse Events (AEs) with letermovir: Refers to any unwanted or harmful effects experienced by patients using letermovir, such as nausea, vomiting, diarrhea, headaches, or elevated liver enzymes. These events can vary in severity and may or may not be related to the medication.

    Time frame: within 24 weeks following HSCT

  6. CMV disease-related mortality within 24 weeks post-transplant

    CMV disease-related mortality: Refers to deaths directly caused by complications of CMV (cytomegalovirus) infection, such as CMV viremia, organ damage, or CMV-related immunosuppression, leading to fatal outcomes.

    Time frame: within 24 weeks following HSCT

  7. All-cause mortality and non-relapse mortality within 24 weeks post-transplant

    All-cause mortality: Refers to deaths from any cause, including disease relapse, treatment complications, or unrelated factors, providing an overall measure of survival. Non-Relapse Mortality (NRM): Refers to deaths unrelated to disease relapse or progression, typically caused by treatment complications such as infections, organ failure, or graft-versus-host disease (GVHD). Non-relapse mortality (NRM): Refers to deaths unrelated to disease relapse or progression, typically caused by treatment complications such as infections, organ failure, or graft-versus-host disease (GVHD).

    Time frame: within 24 weeks following HSCT

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2026, 17 months after the start.

Of 23 interventional studies with no phase under Cytomegalovirus Infections, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2025
First posted
Feb 6, 2025
StartActual
Dec 16, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06812598
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Dec 16, 2024
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 21, 2026

Study contacts

Xiaojin Wu, Prof.
Contact
wuxiaojin@suda.edu.cn
13057493105
Xiaojin Wu, Prof.
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion